Studie - Erosive Oral Lichen Planus – Pipeline Review, H1 2012

Erosive Oral Lichen Planus — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Erosive Oral Lichen Planus - Pipeline Review, H1 2012', provides an overview of the Erosive Oral Lichen Planus therapeutic pipeline. This report provides information on the therapeutic development for Erosive Oral Lichen Planus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erosive Oral Lichen Planus. 'Erosive Oral Lichen Planus - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Erosive Oral Lichen Planus.
- A review of the Erosive Oral Lichen Planus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Erosive Oral Lichen Planus pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Erosive Oral Lichen Planus.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Erosive Oral Lichen Planus pipeline depth and focus of Erosive Oral Lichen Planus therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Erosive Oral Lichen Planus Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Erosive Oral Lichen Planus 7

Erosive Oral Lichen Planus Therapeutics under Development by Companies 9

Erosive Oral Lichen Planus Therapeutics under Investigation by Universities/Institutes 10

Late Stage Products 11

Comparative Analysis 11

Mid Clinical Stage Products 12

Comparative Analysis 12

Pre-Clinical Stage Products 13

Comparative Analysis 13

Erosive Oral Lichen Planus Therapeutics — Products under Development by Companies 14

Erosive Oral Lichen Planus Therapeutics — Products under Investigation by Universities/Institutes 15

Companies Involved in Erosive Oral Lichen Planus Therapeutics Development 16

BioAlliance Pharma SA 16

Erosive Oral Lichen Planus — Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Drug Profiles 22

Corticosteroid Lauriad - Drug Profile 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Amevive - Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Etanercept - Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Etanercept - Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Curcuminoids - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Minocycline - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Rapamune - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Erosive Oral Lichen Planus Therapeutics — Discontinued Products 30

Erosive Oral Lichen Planus Therapeutics - Dormant Products 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 33

Disclaimer 33





List of Tables

Number of Products Under Development for Erosive Oral Lichen Planus, H1 2012 7

Products under Development for Erosive Oral Lichen Planus — Comparative Analysis, H1 2012 8

Number of Products under Development by Companies, H1 2012 9

Number of Products under Investigation by Universities/Institutes, H1 2012 10

Comparative Analysis by Late Stage Development, H1 2012 11

Comparative Analysis by Mid Clinical Stage Development, H1 2012 12

Comparative Analysis by Pre-Clinical Stage Development, H1 2012 13

Products under Development by Companies, H1 2012 14

Products under Investigation by Universities/Institutes, H1 2012 15

BioAlliance Pharma SA, H1 2012 16

Assessment by Monotherapy Products, H1 2012 17

Assessment by Stage and Route of Administration, H1 2012 19

Assessment by Stage and Molecule Type, H1 2012 21

Erosive Oral Lichen Planus Therapeutics — Discontinued Products 30

Erosive Oral Lichen Planus Therapeutics — Dormant Products 31





List of Figures

Number of Products under Development for Erosive Oral Lichen Planus, H1 2012 7

Products under Development for Erosive Oral Lichen Planus — Comparative Analysis, H1 2012 8

Products under Development by Companies, H1 2012 9

Products under Investigation by Universities/Institutes, H1 2012 10

Late Stage Products, H1 2012 11

Mid Clinical Stage Products, H1 2012 12

Pre-Clinical Stage Products, H1 2012 13

Assessment by Monotherapy Products, H1 2012 17

Assessment by Route of Administration, H1 2012 18

Assessment by Stage and Route of Administration, H1 2012 19

Assessment by Molecule Type, H1 2012 20

Assessment by Stage and Molecule Type, H1 2012 21

• Adult Mouth Care in Canada
• Adult Mouth Care in Denmark
• Adult Mouth Care in Hong Kong, China
• Adult Mouth Care in Norway
• Adult Mouth Care in Turkey
• Adult Mouth Care in Algeria
• Adult Mouth Care in Azerbaijan
• Adult Mouth Care in Chile
• Adult Mouth Care in China
• Adult Mouth Care in Finland
• Adult Mouth Care in Greece
• Adult Mouth Care in Kazakhstan
• Adult Mouth Care in Latvia
• Adult Mouth Care in Lithuania
• Adult Mouth Care in Poland
• Adult Mouth Care in Sweden
• Adult Mouth Care in the US
• Adult Mouth Care in Uzbekistan
• Adult Mouth Care in Australia
• Adult Mouth Care in Croatia